Unknown

Dataset Information

0

Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist ?-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.


ABSTRACT: The progressive tumor microenvironment (TME) coordinately supports tumor cell expansion and metastasis, while it antagonizes the survival and (poly-)functionality of antitumor T effector cells. There remains a clear need to develop novel therapeutic strategies that can transform the TME into a pro-inflammatory niche that recruits and sustains protective immune cell populations. While intravenous treatment with tumor-primed CD4+ T cells combined with intraperitoneal delivery of agonist anti-glucocorticoid-induced TNF receptor (?-GITR) mAb results in objective antitumor responses in murine early stage disease models, this approach is ineffective against more advanced tumors. Further subcutaneous co-administration of a vaccine consisting of tumor antigen-loaded dendritic cells (DC) failed to improve the antitumor efficacy of this approach. Remarkably, these same three therapeutic agents elicited significant antitumor benefits when the antitumor CD4+ T cells and tumor antigen-loaded DC were co-injected directly into tumors along with intratumoral or intraperitoneal delivery of ?-GITR mAb. This latter protocol induced the production of an array of antitumor cytokines and chemokines within the TME, supporting increased tumor-infiltration by antitumor CD8+ T cells capable of mediating tumor regression and extended overall survival.

SUBMITTER: Liu Z 

PROVIDER: S-EPMC5486177 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4<sup>+</sup> T cells combined with agonist α-GITR mAb promotes durable CD8<sup>+</sup> T-cell-dependent antitumor immunity.

Liu Zuqiang Z   Hao Xingxing X   Zhang Yi Y   Zhang Jiying J   Carey Cara D CD   Falo Louis D LD   Storkus Walter J WJ   You Zhaoyang Z  

Oncoimmunology 20170424 6


The progressive tumor microenvironment (TME) coordinately supports tumor cell expansion and metastasis, while it antagonizes the survival and (poly-)functionality of antitumor T effector cells. There remains a clear need to develop novel therapeutic strategies that can transform the TME into a pro-inflammatory niche that recruits and sustains protective immune cell populations. While intravenous treatment with tumor-primed CD4<sup>+</sup> T cells combined with intraperitoneal delivery of agonist  ...[more]

Similar Datasets

| S-EPMC6888973 | biostudies-literature
| S-EPMC6368904 | biostudies-literature
| S-EPMC7451475 | biostudies-literature
| S-EPMC4475992 | biostudies-literature
| S-EPMC3117911 | biostudies-literature
| S-EPMC6407574 | biostudies-literature
| S-EPMC2731416 | biostudies-literature
| S-EPMC7277028 | biostudies-literature
| S-EPMC6205479 | biostudies-literature
| S-EPMC2862699 | biostudies-literature